150,398 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC purchased a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 150,398 shares of the company’s stock, valued at approximately $7,690,000. Segall Bryant & Hamill LLC owned 0.16% of Crinetics Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Swiss National Bank lifted its position in shares of Crinetics Pharmaceuticals by 0.5% during the 3rd quarter. Swiss National Bank now owns 130,900 shares of the company’s stock valued at $6,689,000 after acquiring an additional 600 shares during the period. Commerce Bank bought a new stake in Crinetics Pharmaceuticals in the third quarter valued at $212,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Crinetics Pharmaceuticals by 2.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 20,633 shares of the company’s stock valued at $1,054,000 after purchasing an additional 505 shares during the period. Advisors Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,806 shares of the company’s stock worth $143,000 after purchasing an additional 1,008 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at about $1,142,000. 98.51% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, COO Jeff E. Knight sold 7,162 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $244,940.40. Following the sale, the chief operating officer now directly owns 87,491 shares in the company, valued at $2,992,192.20. The trade was a 7.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dana Pizzuti sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total value of $195,350.00. Following the transaction, the insider now directly owns 31,748 shares in the company, valued at $1,240,394.36. This represents a 13.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,015 shares of company stock worth $1,119,263 over the last three months. 6.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CRNX. Wolfe Research began coverage on Crinetics Pharmaceuticals in a report on Tuesday, February 4th. They issued a “peer perform” rating on the stock. Stifel Nicolaus began coverage on Crinetics Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $60.00 target price on the stock. Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. Finally, TD Cowen began coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Crinetics Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $73.00.

Crinetics Pharmaceuticals Trading Down 1.6 %

Shares of Crinetics Pharmaceuticals stock opened at $34.51 on Thursday. The business’s fifty day simple moving average is $36.10 and its 200 day simple moving average is $47.77. Crinetics Pharmaceuticals, Inc. has a 12 month low of $31.84 and a 12 month high of $62.53. The firm has a market capitalization of $3.21 billion, a P/E ratio of -9.25 and a beta of 0.58.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.